FR3139821B1 - Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations - Google Patents

Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations

Info

Publication number
FR3139821B1
FR3139821B1 FR2209320A FR2209320A FR3139821B1 FR 3139821 B1 FR3139821 B1 FR 3139821B1 FR 2209320 A FR2209320 A FR 2209320A FR 2209320 A FR2209320 A FR 2209320A FR 3139821 B1 FR3139821 B1 FR 3139821B1
Authority
FR
France
Prior art keywords
fragment
hybrid molecule
antibody
peptide binding
autoimmune dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2209320A
Other languages
English (en)
Other versions
FR3139821A1 (fr
Inventor
Cyril Clavel
Caroline Carle
Guy Serre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Montpellier
Centre Hospitalier Universitaire de Toulouse
University of Montpellier
Arthritis Recherche et Developpement SAS
Université de Toulouse
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Montpellier
Centre Hospitalier Universitaire de Toulouse
University of Montpellier
Universite Toulouse III Paul Sabatier
Arthritis Recherche et Developpement SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Montpellier, Centre Hospitalier Universitaire de Toulouse, University of Montpellier, Universite Toulouse III Paul Sabatier, Arthritis Recherche et Developpement SAS filed Critical Institut National de la Santé et de la Recherche Médicale
Priority to FR2209320A priority Critical patent/FR3139821B1/fr
Priority to EP23793000.3A priority patent/EP4587469A1/fr
Priority to PCT/FR2023/051403 priority patent/WO2024056978A1/fr
Priority to US19/111,946 priority patent/US20260091122A1/en
Publication of FR3139821A1 publication Critical patent/FR3139821A1/fr
Application granted granted Critical
Publication of FR3139821B1 publication Critical patent/FR3139821B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L’invention concerne une molécule hybride comprenant au moins un fragment Fc d’anticorps lié de façon covalente à au moins un peptide se liant à un lymphocyte auto-réactif responsable d’une dermatite auto-immune, les utilisations d’une telle molécule hybride, ainsi que son procédé de production. (pas de figure)
FR2209320A 2022-09-15 2022-09-15 Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations Active FR3139821B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR2209320A FR3139821B1 (fr) 2022-09-15 2022-09-15 Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations
EP23793000.3A EP4587469A1 (fr) 2022-09-15 2023-09-15 Molécule hybride comprenant un fragment fc d'anticorps et au moins un peptide se liant à un lymphocyte auto-réactif, impliqué dans une dermatite auto-immune, et ses utilisations
PCT/FR2023/051403 WO2024056978A1 (fr) 2022-09-15 2023-09-15 Molécule hybride comprenant un fragment fc d'anticorps et au moins un peptide se liant à un lymphocyte auto-réactif, impliqué dans une dermatite auto-immune, et ses utilisations
US19/111,946 US20260091122A1 (en) 2022-09-15 2023-09-15 Hybrid Molecule Comprising an Antibody FC Portion and at Least One Peptide Binding to a Self-Reactive Lymphocyte Involved in Autoimmune Dermatitis, and Uses Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2209320 2022-09-15
FR2209320A FR3139821B1 (fr) 2022-09-15 2022-09-15 Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations

Publications (2)

Publication Number Publication Date
FR3139821A1 FR3139821A1 (fr) 2024-03-22
FR3139821B1 true FR3139821B1 (fr) 2025-12-12

Family

ID=85278027

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2209320A Active FR3139821B1 (fr) 2022-09-15 2022-09-15 Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations

Country Status (4)

Country Link
US (1) US20260091122A1 (fr)
EP (1) EP4587469A1 (fr)
FR (1) FR3139821B1 (fr)
WO (1) WO2024056978A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4703371A1 (fr) * 2024-09-03 2026-03-04 SeraDiaLogistics Propriétés diagnostiques et thérapeutiques d'épitopes peptidiques dérivés de protéines d'adhésion matricielle extracellulaires de pemphigoïde bulleuses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008231036A (ja) * 2007-03-20 2008-10-02 Hokkaido Univ ポリペプチドを有効成分とする自己免疫性皮膚疾患治療薬
CA2813411C (fr) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Conjugues de polypeptides obtenus par genie biologique, et procede de fabrication correspondants au moyen de transglutaminase
JP6865584B2 (ja) 2013-12-23 2021-04-28 コヴァラブ 化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
EP4169944A1 (fr) * 2014-03-14 2023-04-26 Biomolecular Holdings LLC Procédé de préparation d'immunoglobuline hybride contenant une liaison non peptidyle
ES2773917T3 (es) * 2014-07-30 2020-07-15 Topas Therapeutics Gmbh Péptidos de la desmogleína 3 en pénfigo vulgar
US20200291115A1 (en) * 2019-03-15 2020-09-17 The Broad Institute, Inc. Compositions and methods for treating diseases

Also Published As

Publication number Publication date
WO2024056978A1 (fr) 2024-03-21
US20260091122A1 (en) 2026-04-02
EP4587469A1 (fr) 2025-07-23
FR3139821A1 (fr) 2024-03-22

Similar Documents

Publication Publication Date Title
Petrotchenko et al. An isotopically coded CID-cleavable biotinylated cross-linker for structural proteomics
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
Guan et al. LC− MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin α in equine plasma
Zhao et al. Identification of proteins interacting with ubiquitin chains
Matsuda et al. Application of native ion exchange mass spectrometry to intact and subunit analysis of site-specific antibody–drug conjugates produced by ajicap first generation technology
BR0315270A (pt) Anticorpo isolado ou um fraguemento de anticorpo que se liga a antìgeno, anticorpo monoclonal, hibridona, molécula de ácido nucleico isolada, composição farmacêutica, artigo de fabricação, polipeptìdeo de fusão e métodos para melhorar um sintoma de um distúrbio relacionado com o ca125/0772p e para ajudar na identificação de um anticorpo ou fragmento de anticorpo que se liga a antìgeno
BR112022026401A2 (pt) Conjugados anticorpo-fármaco compreendendo anticorpos anti-b7-h3
Costa et al. Investigating LGALS3BP/90 K glycoprotein in the cerebrospinal fluid of patients with neurological diseases
Yu et al. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes
WO2011129357A1 (fr) Complexe d'une sonde marquée et d'un vecteur hydrosoluble
São Pedro et al. Minimizing the Influence of Fluorescent Tags on IgG Partition in PEG–Salt Aqueous Two‐Phase Systems for Rapid Screening Applications
Schaller et al. Pharmacokinetic analysis of a novel human EGFRvIII: CD3 bispecific antibody in plasma and whole blood using a high-resolution targeted mass spectrometry approach
MA54969B2 (fr) Anticorps monoclonal se liant spécifiquement à gitr
Kopylov et al. Combined use of irreversible binding and MRM technology for low‐and ultralow copy‐number protein detection and quantitation
BR112023023270A2 (pt) Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1
FR3139820B1 (fr) Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une vascularite auto-immune, et ses utilisations
Nath et al. On-bead antibody-small molecule conjugation using high-capacity magnetic beads
Stüber et al. Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies
Xu et al. Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry
Matrat et al. Characterization of a severe hypofibrinogenemia induced by alteplase in two patients thrombolysed for stroke
Ayoubi et al. The identification of high-performing antibodies for Sequestosome-1 for use in Western blot, immunoprecipitation and immunofluorescence
Tang et al. Streptolysin O accelerates the conversion of plasminogen to plasmin
Ramm et al. Investigation of native and aggregated therapeutic proteins in human plasma with asymmetrical flow field-flow fractionation and mass spectrometry: Ramm I. et al.
Watson et al. Defining the features of complement-active IgM

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4